Advances in Inpatient Diabetes Care

A special issue of Diabetology (ISSN 2673-4540).

Deadline for manuscript submissions: 20 January 2027 | Viewed by 949

Editor


E-Mail Website
Guest Editor
1. South West Clinical School, UNSW Medicine, Sydney, Australia
2. Diabetes & Endocrinology, Liverpool Hospital, Liverpool, Australia
3. Liverpool Diabetes Collaboration, Ingham Institute of Applied Medical Research, Liverpool, Australia
Interests: diabetes mellitus; diabetes related foot disease; diabetes and hospitalisation; cardio-metabolic risk; overweight/obesity

Special Issue Information

Dear Colleagues,

The last decade has seen wide advances across the range of diabetes care, from strong evidence of combined glucose, renal and cardiac benefits of sodium glucose co-transporter agents, and for incretins added metabolic effects which have transformed the therapeutic space for Type 2 diabetes to technology radically changing the measurement of blood glucose levels and in Type 1 diabetes, embedding this into devices that use real-time blood glucose measures to minutely regulate insulin release. Collectively, these have significantly improved the lived experience of people with diabetes mellitus.

However, when this same period is looked through the lenses of demography and public health, it is marked by an increasing prevalence of the condition, especially Type 2 diabetes, and increasing numbers of people with diabetes needing access to acute hospital care; despite these advances, those with diabetes are hospitalised and have poorer outcomes than those without diabetes.

This Special Issue, titled “Advances in Inpatient Diabetes Care”, is an excellent opportunity to consider by how much and to what degree the advances in clinical and therapeutics for diabetes impact care in the hospital, how technology provides different ways of managing blood glucose levels, how clinical practice guidelines, including those for hyperglycaemic emergencies, operate at the ward level, and how inpatient-related diabetes care transitions through to discharge and beyond. We welcome original research, review articles, and forward-looking perspectives that address these critical facets of hospital-based diabetes care.

Dr. Namson Lau
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • drug therapy
  • hospitalisation
  • hypoglycaemia
  • hyperglycaemia
  • inpatients
  • blood glucose
  • metabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1216 KB  
Article
A Pragmatic Cluster-Randomized Trial of Insulin Therapy for Dexamethasone-Induced Hyperglycemia Amongst Diabetes Patients with COVID-19
by Ngai Wah Cheung, Amanda Hor, Simone Marschner, Christopher Chan, Haeri Min, Lauren Lee, Tien-Ming Hng, Yoon Ji Jina Rhou, Yu-Fang Wu, Mawson Wang and David R. Chipps
Diabetology 2026, 7(5), 94; https://doi.org/10.3390/diabetology7050094 - 9 May 2026
Viewed by 602
Abstract
Background: Glucocorticoid-induced hyperglycemia is common amongst hospitalized patients. Isophane insulin has been proposed as part of the optimal insulin regimen for managing this, but there are few randomized controlled trials to support this. Our aim was to determine if the addition of a [...] Read more.
Background: Glucocorticoid-induced hyperglycemia is common amongst hospitalized patients. Isophane insulin has been proposed as part of the optimal insulin regimen for managing this, but there are few randomized controlled trials to support this. Our aim was to determine if the addition of a morning dose of isophane insulin would improve glycemic control amongst patients with COVID-19 who had dexamethasone-induced hyperglycemia (DIH) in hospital. Methods: Patients with diabetes admitted to hospital with COVID-19 respiratory infection and treated with dexamethasone were cluster-randomized by ward to receive either basal bolus insulin (BBI) or isophane-augmented BBI (IaBBI) in equipotent doses. Insulin commencement and titration were guided by standardized protocols. The primary outcome was overall finger-prick blood glucose (BG) levels, with predefined secondary outcomes of BGs on day 3 and the final day of admission. Results: A total of 40 patients were included, 25 in the IaBBI group and 15 in the BBI only group, for a duration of 5.4 ± 2.2 days. Both recruitment and the trial were terminated early because of a rapid decline in COVID-19 admissions. There were no differences in overall mean BG levels (IaBBI 11.9 ± 2.5 mmol/L vs. BBI 12.6 ± 2.4 mmol/L, p = 0.193) between the groups. Mean day 3 BGs were lower in the IaBBI group than in the BBI group (11.1 ± 3.5 mmol/L vs. 12.7 ± 3.5 mmol/L, p = 0.029) and on the final day (9.6 ± 2.8 mmol/L vs. 10.7 ± 2.5 mmol/L, respectively, p = 0.011). Conclusions: The restricted sample size in this study limits any conclusions that can be made regarding the effectiveness of the addition of isophane insulin to a BBI insulin regimen for diabetes patients with COVID-19 infection and DIH. However, some improvements in glycemic control were observed, suggesting that this is a glucose management strategy that warrants further evaluation. Full article
(This article belongs to the Special Issue Advances in Inpatient Diabetes Care)
Show Figures

Graphical abstract

Back to TopTop